Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 16/20 | 0.42 |
| ▸ | TLR8 | Q9NR97 | 8/20 | 0.42 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.41 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.40 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1457538 | 0.92 | TLR7 (0.47) | TLR7TLR8NUDT1CYP11B1CYP11B2 | |
| SCHEMBL1456913 | 0.90 | TLR8 (0.42) | TLR7TLR8NUDT1CYP2E1CYP2A6 | |
| SCHEMBL1456981 | 0.90 | TLR7 (0.55) | TLR7TLR8NUDT1 | |
| SCHEMBL1457535 | 0.86 | TLR7 (0.44) | TLR7TLR8NUDT1 | |
| SCHEMBL1456611 | 0.84 | TLR7 (0.48) | TLR7TLR8NUDT1 | |
| SCHEMBL1457532 | 0.82 | TLR8 (0.47) | TLR7TLR8NUDT1 | |
| SCHEMBL1457222 | 0.82 | TLR7 (0.62) | TLR7TLR8NUDT1 | |
| SCHEMBL1456656 | 0.81 | TLR8 (0.54) | TLR7TLR8NUDT1 | |
| SCHEMBL1457399 | 0.78 | CYP2E1 (0.43) | TLR7TLR8NUDT1CYP2E1CYP2A6 | |
| SCHEMBL1457018 | 0.77 | TLR7 (0.46) | TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7915281-B2 | Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and method | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2011-03-29 | — | — | US | disclosed |
| US-20070287725-A1 | Isoxazole, Dihydroisoxazole, And Oxadiazole Substituted Imidazo Ring Compounds And Method | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2007-12-13 | — | — | US | disclosed |
| WO-2006065280-A2 | ISOXAZOLE, DIHYDROISOXAZOLE, AND OXADIAZOLE SUBSTITUTED IMIDAZO RING COMPOUNDS AND METHODS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2006-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070287725-A1 | Isoxazole, Dihydroisoxazole, And Oxadiazole Substituted Imidazo Ring Compounds And Method | IFNG, IL4, IL2 | TLR7 137/4885TLR8 541/4885NUDT1 350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.